Chengdu Kanghong Biotech Co., Ltd. clinical trials

A subsidiary of Chengdu Kanghong Pharmaceutical Group Co., Ltd.

The registry lists 21 studies whose lead sponsor is Chengdu Kanghong Biotech Co., Ltd.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 9, 2026.

Studies

Recruiting first, then most recently updated. Showing 21 of 21. All Chengdu Kanghong Pharmaceutical Group Co., Ltd. studies →

• First-In-Human Study of KHN922 for InjectionNot yet recruitingNCT07514975Phase 1/2

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• First-In-Human Study in Participants With Advanced Solid TumorsNot yet recruitingNCT06885645Phase 1

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMDCompletedNCT01436864Phase 3

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World DataStatus unknownNCT04985448

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein OcclusionCompletedNCT03108352Phase 3

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• Conbercept Ophthalmic Injection for Patients of Central Retinal Vein OcclusionCompletedNCT03223714Phase 3

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of RetinoblastomaStatus unknownNCT04990271Phase 2

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)TerminatedNCT03577899Phase 3

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)TerminatedNCT03630952Phase 3

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line TherapyStatus unknownNCT04555304Phase 2

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal NeovascularizationStatus unknownNCT04215393Phase 1

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal VasculopathyStatus unknownNCT03244657Phase 4

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)Status unknownNCT03159884Phase 4

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word（STONE）Status unknownNCT03054818

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)Status unknownNCT02194634Phase 3

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMDCompletedNCT01157715Phase 2

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)Status unknownNCT02098720Phase 2

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNVStatus unknownNCT01809223Phase 3

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein OcclusionStatus unknownNCT01809236Phase 2

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMDCompletedNCT01242254Phase 1/2

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.

• Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME)CompletedNCT01324869Phase 1/2

  Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.